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Background I 
• Obesity is a risk factor for the development of venous 
thromboembolism (VTE) 
• Incidence of symptomatic deep vein thrombosis (DVT) ranges from 
0%-5.4 % 
• Incidence of  pulmonary embolism (PE) ranges 0%-6.4 % 
 
• VTE (extended) chemoprophylaxis is recommended 
• No high evidence for type, dose, or duration of VTE prophylaxis (low-
molecular-weight heparin) 
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Background II 
• Rivaroxaban (Xarelto ®) is a new oral anticoagulant 
(NOAC) that directly inhibits factor Xa  
• It has proven to be safe and effective in the (extended) 
prevention of venous thromboembolism after total hip or 
knee replacement 
• Until now there is no systematic investigation of Xarelto ® 
in obese patients undergoing bariatric surgery 
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Aim of the study 
 
 
To investigate pharmacokinetic (PK) and pharmacodynamic (PD) 
parameters of Rivaroxaban in the perioperative bariatric setting. 
 
This trial investigates a new indication, i.e. thrombosis prophylaxis in 
bariatric surgery and it could be an alternative option to LMWH 
prophylaxis. 
 
 
                  
Objectives 
Primary objectives  
To compare the PK of single doses of 10 mg rivaroxaban in patients 
before and after two different bariatric surgery procedures 
Secondary objectives  
 To assess the PD before and after bariatric surgery  
 To assess the safety and tolerability after Sleeve Gastrectomy and 
Roux-en-Y gastric bypass  
 
Outcomes 
Pharmacokinetic parameters 
• Area under plasma concentration curve (AUC)  pre versus post bariatric surgery  
• Maximum plasma concentration (Cmax) before and after bariatric surgery  
• Time of maximum plasma concentration (Tmax) before and after bariatric 
surgery  
 
Pharmacodynamic parameters: 
• Prothrombin time (PT) 
• Activated partial thromboplastin time (aPTT)  
• Prothrombin fragments (F1+F2) 
• Thrombin-antithrombin-complexes (TAT)  
• D-Dimers 
• Thrombin generation   
 
Study Design und Procedure 
• Open label phase 1 clinical trial 
• Intervention: 10 mg rivaroxaban  as a single application before and 
after bariatric surgery 
•  Objectives: to assess PK/PD and safety parameters of rivaroxaban in 
this specific study population.   
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Inclusion criteria 
• Scheduled elective bariatric surgery: laparoscopic Roux-en-Y gastric 
bypass surgery or sleeve resection  
• 18 years and older  
• BMI ≥ 35 kg/m2  
• Women of child-bearing age: Willingness of using a double barrier 
contraception method during the study  
• Written, informed consent  
  
 
Exclusion criteria 
• TVE in history 
• Myocardial infarction, transient ischemic attack or stroke within 
6 months of study entry 
• Severe hypertension 
• Severely impaired hepatic or renal function (creatinine clearance <30 
mL per min) 
• Concomitant use of drugs that strongly inhibit cytochrome CYP3a4, 
such as protease inhibitors or ketoconazole 
•  … 
 
Results Baseline characteristics 
Results PK Roux-en-Y gastric bypass 
Results PK Gastric Sleeve 
Plasma concentration–time profiles for 1.25 to 80 mg in 
healthy subjects  
Results PK Roux-en-Y-gastric bypass and Sleeve 
Rivaroxaban concentration by type of surgery 
 
 
Safety analysis 
• No major bleeding 
• Most common AEs were nausea and headache  
• One serious adverse event (SAE) due to a surgical 
complication which resulted in study discontinuation 
Conclusion 
• Rivaroxaban was well tolerated and safe  
• There was no significant difference in pharmacokinetic 
parameters before and shortly after bariatric surgery 
independent of the bariatric procedure (SG or RYGB).  
• Resorption of rivaroxaban was rapidly and not significantly 
impaired by bariatric surgery 
Outlook 
• Based on these results rivaroxaban can be investigated in a phase 2 
clinical trial in the perioperative bariatric setting 
• “Extention study” accepted by KEK and SWISSMEDIC 
• Therapeutic dose of rivaroxaban (20 mg) in high risk patients with 
preexisting anticoagulation therapy 
• Evaluation in the postoperative setting of other visceral surgery patients, 
especially for extended treatment after abdominal cancer surgery 
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